Clinical and Associated Immunological Manifestations of HFMD Caused by Different Viral Infections in Children

Jingjing Wang, MS¹, Jing Pu, PhD¹, Longding Liu, PhD¹, Yanchun Che, MS¹, Yun Liao¹, Lichun Wang¹, Lei Guo, PhD¹, Min Feng, PhD¹, Yan Liang, PhD¹, Shengtao Fan, PhD¹, Lukui Cai, MS¹, Ying Zhang, PhD¹, and Qihan Li, PhD, MD¹

Abstract
Hand, foot, and mouth disease (HFMD), with vesiculae on the hands, feet and mouth, is an infectious disease caused by many viral pathogens. However, the differences of immune response induced by these pathogens are unclear. We compared the clinical manifestations and the levels of immunologic indicators from 60 HFMD patients caused by different viral pathogens to analyze the differences in the immune response. It was shown that Th2 cytokines (IL-4 and IL-10) increased significantly in EV71-infected children; Th1 cytokines (IL-2 and IFN-γ) rose in CA16-infected children; both Th1 and Th2 cytokines elevated in non-EVG-infected children; only individual cytokines (such as IL-10) went up in EVG-infected children. Meanwhile, the antibodies induced by viral infection could not cross-interfere between the different pathogens. These differences might be due to variations in the immune response induced by the individual pathogens or to the pathogenesis of the infections by the individual pathogens.

Keywords
hand foot and mouth disease (HFMD), enterovirus 71 (EV71), coxsackievirus group A type 16 (CA16), cytokines, chemokines

Received March 3, 2016. Accepted for publication March 8, 2016

Introduction
In recent years, hand, foot, and mouth disease (HFMD) has been widely recognized as a highly infectious condition in children less than 5 years of age, especially in coastal areas of the Asian-Pacific region.¹³ On the Chinese mainland, outbreaks of HFMD have received substantial attention since 2008, following a large outbreak in Fuyang, Anhui Province.⁴ Throughout the Chinese mainland, more than 12 million HFMD cases and 3200 deaths have been reported to date.⁵,₁¹ The typical clinical manifestations of HFMD include vesicular eruptions and rashes on the hands, feet, and mouth and, in some cases, fever.¹²,¹³ Although these clinical manifestations are frequently mild and the prognosis is good, several children develop remarkable systemic neurological symptoms that lead to neurogenic pulmonary edema, cardiac and pulmonary failure, and other severe complications.¹³-¹⁶ Rapid disease progression can lead to death within 24 to 48 hours.¹⁷,¹⁸

Molecular epidemiologic data have demonstrated that the most common pathogens causing HFMD are enterovirus, coxsackievirus, and echovirus.¹⁹,²⁰ Some characteristics of HFMD caused by these pathogens were similar, such as pathologic examinations show the presence of viral antigens in infected tissues,²¹,²² together with the increased expression of pro-inflammatory cytokines in the peripheral blood and, in severe infections,
the cerebrospinal fluid. However, more than 80% of the severe cases and 90% of the deaths in HFMD are caused by enterovirus 71 (EV71) rather than by other viruses. Importantly, repeated infections frequently develop in cases of coxsackievirus group A type 16 (CA16) infection, although CA16 infection usually leads to mild illness. These differences in the severity and appearance of HFMD suggest that the special immune responses were induced by the various pathogens.

In this study, we compared the clinical manifestations and associated immunologic indicators, including cytokines and chemokines, in the serum of HFMD patients to analyze the differences in the immune response and whether they were related to infection by a particular viral pathogen.

**Materials and Methods**

**Ethics**

HFMD patients were recruited from the placebo-controlled group of a phase III trial of an EV71 inactivated vaccine (prepared from human diploid cells). The clinical protocol and informed consent form were approved by the Ethics Committee of the Guangxi Center for Disease Control and Prevention (Guangxi CDC). The clinical protocol is registered in the ClinicalTrials website (NCT01569581).

**HFMD Patients**

Informed consent was obtained from the guardians of the 60 pediatric HFMD patients in the placebo-controlled group. These consisted of 16 patients positive for EV71 infection, 11 with positive CA16 infection, 15 positive for other enterovirus infections (EVG), and 18 who were negative for enterovirus infection (non-EVG). In parallel with the samples collected from these patients, samples from 5 healthy children without any clinical manifestations of HFMD who had also been included in the placebo-controlled group were also obtained.

**Clinical Manifestations**

The patients were observed for clinical manifestations, including vesicles, elevated body temperature, cough, and runny nose, according to the Guidelines for HFMD Diagnosis and Treatment, version 2010, published by the National Health and Family Planning Commission.

**Viral Etiology**

Viral RNA was extracted from the stool samples or the throat swabs of the HFMD patients using the RNeasy mini kit (Qiagen, Hilden, Germany). Etiological detection was carried out by real-time polymerase chain reaction, performed at the Guangxi CDC laboratories. The results were reconfirmed by the National Institutes for Food and Drug Control (NIFDC).

**Cytokine and Chemokine Detection**

The levels of cytokines and chemokines in the sera of the HFMD patients and controls (healthy children) were measured using Bio-Plex Pro human cytokine and chemokine kits (Bio-Rad, Hercules, CA) according to the manufacturer’s protocols. This kit contains beads conjugated with monoclonal antibodies specific for IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, and others. Briefly, samples suspended in buffer were transferred to plates, incubated at room temperature for 1 hour with shaking at 850 ± 50 rpm, and then washed with the same buffer 3 times. Detection antibodies were added to the plates, which were then incubated as above for another 0.5 hours and then washed 3 times with the same buffer. SA-PE solution (Bio-Rad) was added to the plates in the dark, which were incubated for 10 minutes with shaking at 850 ± 50 rpm and washed 3 times with buffer. Finally, the beads were added and the samples were incubated with shaking as above for 30 seconds. The reactions were read using a Bio-Plex 200 system (Bio-Rad).

**Anti-EV71 Neutralizing Antibody Detection**

Specific anti-EV71 neutralizing antibody titers were detected using the classical micro-cytopathic effect neutralization assay according to the standard protocol. Briefly, the EV71 standard strain (NIFDC, China) was incubated with sera in different dilution at 37°C for 2 hours, transferred to 96-well plates containing a Vero cell suspension (10^4 per well), and mixed completely. After a 7-day incubation at 37°C, the samples were analyzed for the presence of cytopathic effects.

**Statistical Analysis**

Differences between groups were analyzed using SPSS software (Chicago, IL). A P value <.05 was considered to indicate a statistically significant difference.

**Results**

**Pathogen Distribution of 60 HFMD Cases**

HFMD is most often seen in children under 5 years of age. In this study, HFMD developed in 33 children (33/60, 55%) younger than 2 years of age (Table 1).
Among the 60 patients, 35 were male and 25 were female; 58 of the cases were mild and 2 were severe (Table 1). There was no significant difference between the age or sex of the patients and the degree of symptoms (except $P = .018$ between the CA16 and EVG groups).

### Clinical Manifestations of HFMD Cases Caused by Different Enteroviruses

The typical clinical character of HFMD is vesiculae or rashes on the hands, feet, and mouth. In this study, the typical rashes of the hands, feet, and mouth as well as the perianal region were seen in more than 60% of the patients (Table 2). Fever (body temperature $>37.5^\circ C$) occurred in roughly 50% (Table 2). A few patients also had cough, runny nose, anorexia, and other symptoms (Table 2). In the 2 patients with severe HFMD, in addition to the typical rashes of the hands, feet, and mouth, high fever and oral vesicles developed in one patient, and a fever of $38.5^\circ C$ accompanied by a mild neurological system disorder, manifested as a decreased response to stimulation, in the other (Table 2).

### Cytokine Analysis of HFMD Cases Caused by Different Enteroviruses

Increased levels of pro-inflammatory cytokines have been clearly demonstrated in HFMD patients, especially a remarkable increase in interleukin (IL)-6 in patients with severe EV71 infection. We therefore evaluated cytokine expression in our HFMD patients with respect to the different pathogens. Compared with the healthy children, EV71 infections was associated with high levels of IL-4 and IL-10, and CA16 infections associated with IL-2, IFN-$\gamma$, and IL-4, respectively (Table 3). By contrast, in the patients with HFMD caused by EVG, only an increase in the level of IL-10 was determined (Table 3). Nonenterovirus (non-EVG) infections triggered increases in IL-2, IL-16, IFN-$\gamma$, IL-4, and IL-10 (Table 3). These results suggested that the release of different pro-inflammatory cytokines was triggered by the different pathogens. The pro-inflammatory cytokines of the 2 patients with severe HFMD, caused by infection with CA16 and a non-EVG, respectively, showed similarities, including a clear elevation in IL-6 (Table 3). However, there are higher levels of IL-1 and IL-6 in the patient with the non-EVG infection than those of the patient with severe CA16 infection or the healthy children.

### Chemokine Analysis of HFMD Cases Caused by Different Enteroviruses

Infections with exogenous pathogens trigger usually the release of a large variety of cytokines and chemokines. Our study showed that patients with different pathogen infections had high levels of the chemokines, including CCL1, CXCL6, CXCL12, CXCL13, and CX3CL1 (Table 4). Of these, the levels of CXCL6, CXCL12, and CXCL13 were significantly higher in HFMD patients with infections attributed to all of EV71, CA16, EVG, and non-EVG (Table 4). The level of CXCL5 was lower in HFMD patients with EV71, CA16, and EVG infections than in the healthy children (Table 4). In the 2 patients with severe HFMD, CCL25 levels were significantly higher than in the healthy controls (Table 4). However, in the patient with severe non-EVG HFMD, the levels of CXCL1, CXCL2, CCL3, CCL2, and CCL20 were much higher than in either the patient with severe CA16 infection or the healthy controls (Table 4).
Table 2. Clinical Characteristics of the 60 Patients With HFMD Caused by Different Pathogens.

| Symptoms          | EV71+ | CA16+ | EVG+ | EVG− |
|-------------------|-------|-------|------|------|
| Total cases, n    | 16    | 11    | 15   | 18   |
| Rash, n (%)       | 14 (87.5) | 9 (81.8) | 8 (53.3) | 17 (94.4) |
| Oral herples, n (%)| 9 (56.3) | 9 (81.8) | 11 (73.3) | 6 (33.3) |
| Fever, n (%)      | 6 (37.5) | 6 (54.5) | 11 (73.3) | 11 (73.3) |
| Cough, n (%)      | 1 (6.3) | 2 (18.2) | 3 (20.0) | 4 (22.2) |
| Rhinorrhea, n (%) | 1 (6.3) | 2 (18.2) | 3 (20.0) | 5 (27.8) |
| Herpangina, n (%) | 0 (0)  | 0 (0)  | 4 (26.7) | 0 (0)  |
| Anorexia, n (%)   | 1 (6.3) | 0 (0)  | 1 (6.7) | 0 (0)  |
| Night sweat, n (%)| 0 (0)  | 1 (100.0) | 0 (0)  | 0 (0)  |
| Depression, n (%) | 0 (0)  | 0 (0)  | 0 (0)  | 1 (100.0) |
| Serious cases, n  | 0     | 1     | 0    | 1    |
| Rash, n (%)       | —     | 1 (100.0) | —     | 1 (100.0) |
| Oral herples, n (%)| —     | 1 (100.0) | —     | 0 (0)  |
| Fever, n (%)      | —     | 1 (100.0) | —     | 1 (100.0) |
| Cough, n (%)      | —     | 0 (0)  | —     | 0 (0)  |
| Rhinorrhea, n (%) | —     | 0 (0)  | —     | 0 (0)  |
| Herpangina, n (%) | —     | 0 (0)  | —     | 0 (0)  |
| Anorexia, n (%)   | —     | 0 (0)  | —     | 0 (0)  |
| Night sweat, n (%)| —     | 1 (100.0) | —     | 0 (0)  |
| Depression, n (%) | —     | 0 (0)  | —     | 1 (100.0) |

Abbreviation: HFMD, hand, foot, and mouth disease.

Anti-EV71 Immune Response in HFMD Caused by Different Enteroviruses

Cross-neutralization capacities between different enteroviruses have been demonstrated. Because EV71 infections can cause severe disease and even death, in this study we explored the interference of sera taken from HFMD patients infected with different pathogens against EV71 infection. The results showed that the sera of the patients caused by CA16, EVG, and non-EVG were failed to interfere EV71 infection, namely, being negative for anti-EV71 neutralizing antibody, whereas, as expected, serum from the patient with EV71 infection was positive (Figure 1).

Discussion

HFMD is a highly infectious disease caused by different pathogens and is primarily seen in children. The basic clinical manifestations of HFMD in the majority of cases consist of rashes and vesicles involving the hands, feet, and mouth. However, there is epidemiological and immunological evidence of different manifestations of HFMD depending on the infecting strain of virus, in terms of both the pathology and the immune response. In this study, in accordance with the Good Clinical Practice guidelines and the Ethics Committee of our institution, we evaluated the clinical records and serum samples of 60 pediatric HFMD patients infected by different viral pathogens. These patients were drawn from the placebo group of a phase III trial of an EV71-inactivated vaccine. They did not show significant difference between the age or sex of the patients and the degree of symptoms. All 60 patients exhibited the typical, aforementioned symptoms of HFMD. In the 33 patients under 2 years of age (55%), fever was also present. In our 2 patients with severe HFMD, the infections were caused by CA16 and a non-EVG infection. However, our sample of 60 patients was too small to confirm viral specificity, such as which strain was easy to cause a severe case.

Furthermore, as functional responses of the host to the infecting pathogens, some special pro-inflammatory cytokines and chemokines were increased in our HFMD patients. These cytokines were associated with the immune system activation, such as CXCL6, which is closely associated with neutrophil migration recruit, CXCL12 and CXCL13, which are associated with B cell migration and recruitment and antibody production.

Although the previous study reported that the levels of IL-6, tumor necrosis factor-α (TNF-α), IP-10, IL-10, MCP-1, or CXCL9 were significantly higher in HFMD patients with neurological symptoms than in either those without or in healthy children, the expression of many chemokines associated with inflammation, except
Table 3. Cytokine Levels of the 60 Patients With HFMD Caused by Different Pathogens.

| Cytokines | EV71+ | CA16+ | EVG+ | EVG− | Control |
|-----------|-------|-------|------|------|---------|
| Total case, n | 16 | 11 | 15 | 18 | 5 |
| Type I and II cytokine receptors (JAK-STAT), mean ± SD | | | | | |
| Th1 cytokine | | | | | |
| IL-2, pg/mL | 28.51 ± 8.98 | 34.66 ± 9.17 | 28.64 ± 12.02 | 35.60 ± 13.55 | 20.02 ± 11.22 |
| IL-16, pg/mL | 1620.98 ± 1812.19 | 1970.28 ± 1842.91 | 1646.48 ± 1437.31 | 2835.49 ± 3235.16 | 536.24 ± 353.99 |
| IFN-γ, pg/mL | 117.88 ± 43.21 | 147.67 ± 46.36 | 123.47 ± 52.32 | 154.58 ± 58.97 | 83.01 ± 46.26 |
| GM-CSF, pg/mL | 292.26 ± 107.17 | 353.88 ± 129.24 | 278.30 ± 119.44 | 365.47 ± 106.14 | 293.07 ± 117.83 |
| Th2 cytokine | | | | | |
| IL-4, pg/mL | 47.05 ± 8.15 | 47.12 ± 6.27 | 42.13 ± 11.63 | 45.81 ± 12.80 | 31.69 ± 11.99 |
| IL-6, pg/mL | 51.76 ± 86.31 | 28.54 ± 13.87 | 68.48 ± 92.65 | 128.31 ± 387.04 | 24.22 ± 17.72 |
| IL-10, pg/mL | 72.69 ± 28.98 | 70.95 ± 19.31 | 75.05 ± 31.79 | 77.34 ± 30.59 | 42.86 ± 24.26 |
| Toll (TLR)/IL-1 Receptors (NFκB), mean ± SD | | | | | |
| IL-1β, pg/mL | 8.58 ± 3.51 | 26.35 ± 59.43 | 9.49 ± 4.81 | 93.45 ± 310.35 | 5.57 ± 3.32 |
| TNF-related receptors (NFκB vs caspases), mean ± SD | | | | | |
| TNF-α, pg/mL | 63.60 ± 25.14 | 131.14 ± 227.72 | 66.00 ± 29.67 | 93.89 ± 79.17 | 46.22 ± 24.72 |

Serious case, n | 0 | 1 | 0 | 1 | — |
| Type I and II cytokine receptors (JAK-STAT), mean ± SD | | | | | |
| Th1 cytokine | | | | | |
| IL-2, pg/mL | — | 30.44 | — | 55.26 | — |
| IL-16, pg/mL | — | 1166.50 | — | 5931.51 | — |
| IFN-γ, pg/mL | — | 137.83 | — | 241.77 | — |
| GM-CSF, pg/mL | — | 358.69 | — | 563.12 | — |
| Th2 cytokine | | | | | |
| IL-4, pg/mL | — | 40.30 | — | 68.17 | — |
| IL-6, pg/mL | — | 20.55 | — | 160972.60 | — |
| IL-10, pg/mL | — | 46.22 | — | 135.33 | — |
| Toll (TLR)/IL-1 Receptors (NFκB), mean ± SD | | | | | |
| IL-1β, pg/mL | — | 8.45 | — | 1254.26 | — |
| TNF-related receptors (NFκB vs caspases), mean ± SD | | | | | |
| TNF-α, pg/mL | — | 50.33 | — | 167.18 | — |

Abbreviation: HFMD, hand, foot, and mouth disease.

a *P* < .05 of EV71-infected case versus non-EV-infected case.
b *P* < .05 of EV71-infected case versus placebo.
c *P* < .05 of CA16-infected case versus non-EV-infected case.
d *P* < .05 of EV-infected case versus non-EV-infected case.
e *P* < .05 of non-EV-infected case versus placebo.

IL-4 and IL-10, did not show any remarkable increase, likely a storm, in most HFMD cases, not even in the 2 severe cases. It is not that the inflammatory responses were milder in the patients caused by non-EV71 virus than those induced by EV71, by which severe cases with neurological symptoms are often caused.

Interestingly, along with the common clinical manifestations of vesicular eruptions on the hands, feet, and mouth, different profiles of cytokine and chemokine responses were noted in our HFMD patients infected by different viruses. These can be summarized as follows: EV71 infections were characterized by significantly increased levels of Th2 cytokines (IL-4 and IL-10) and CA16 infections by significantly increased levels of Th1 cytokines (IL-2 and IFN-γ). By contrast, non-EVG infections seemed to directly trigger parallel increases in both Th1 and Th2 cytokines, whereas in EVG infections variations were detected only in individual cytokines, such as IL-10. Similarly large, virus-specific variations occurred in the levels of multiple chemokines. For example, the levels of CXCL1 were significantly increased in EVG-infected patients, CCL21 in CA16-infected patients, and CCL17 in non-EVG-infected patients. The differences in these immune effectors might be due to variations in the immune response induced by the individual pathogens or to the pathogenesis of the infections by the individual pathogens.

Finally, the neutralizing assay using sera from the HFMD patients showed no cross-interference between the different pathogens that cause HFMD. Our previous data
Table 4. Chemokine Levels of the 60 Patients With HFMD Caused by Different Pathogens.

| Chemokines | EV71+ | CA16+ | EVG+ | EVG− | Control |
|------------|--------|--------|------|------|--------|
| Total cases, n | 16 | 11 | 15 | 18 | 5 |
| **Inflammatory, mean ± SD** | | | | | |
| CCL1, pg/mL | 45.45 ± 10.67 | 44.60 ± 7.86 | 44.95 ± 14.07 | 46.48 ± 14.79 | 34.50 ± 15.48 |
| CCL25, pg/mL | 256.43 ± 187.64 | 954.29 ± 2308.44 | 294.05 ± 190.40 | 312.65 ± 394.05 | 116.25 ± 72.89 |
| CCL8 (IL-8), pg/mL | 220.49 ± 384.84 | 31.72 ± 45.56 | 273.04 ± 576.22 | 78.36 ± 177.04 | 77.21 ± 127.16 |
| CCL9, pg/mL | 694.01 ± 332.37 | 659.44 ± 520.61 | 812.46 ± 548.12 | 803.39 ± 550.31 | 485.12 ± 463.38 |
| CCL10, pg/mL | 396.50 ± 405.85 | 232.02 ± 251.77 | 203.60 ± 151.74 | 522.25 ± 1198.64 | 63.25 ± 46.35 |
| **Noninflammatory, mean ± SD** | | | | | |
| CCL1, pg/mL | 120.58 ± 17.38b | 127.43 ± 27.88d | 116.51 ± 25.03 | 123.71 ± 30.28g | 90.57 ± 31.19b,d,g |
| CCL2 (MCP-1), pg/mL | 97.09 ± 42.09 | 96.62 ± 57.45 | 160.01 ± 234.35 | 98.93 ± 63.87 | 127.31 ± 67.21 |
| CCL3 (MIP-1α), pg/mL | 124.09 ± 239.41 | 26.15 ± 45.95 | 143.41 ± 292.96 | 69.61 ± 173.58 | 69.31 ± 62.75 |
| CCL7 (TECK), pg/mL | 84.95 ± 94.76 | 69.95 ± 50.80 | 66.13 ± 52.60 | 80.79 ± 58.81 | 27.43 ± 19.79 |
| CCL8 (MCP-2), pg/mL | 526.34 ± 419.84 | 480.34 ± 259.03 | 465.24 ± 269.64 | 621.59 ± 404.69g | 185.00 ± 122.51g |
| CCL9 (MIP-3β), pg/mL | 835.41 ± 556.70b | 781.79 ± 391.45 | 778.23 ± 466.57 | 982.24 ± 601.70g | 315.56 ± 209.32b,g |
| CCL10 (MIP-3α), pg/mL | 18.00 ± 4.93 | 110.21 ± 32.98 | 23.72 ± 20.01 | 22.44 ± 11.62 | 9.92 ± 5.01 |
| CCL11, pg/mL | 1795.84 ± 590.16 | 236.52 ± 913.84a | 1770.99 ± 981.46 | 1647.69 ± 636.39a | 1259.53 ± 689.75a |
| CCL12 (MDC), pg/mL | 1608.23 ± 952.16 | 1253.13 ± 719.74 | 1476.44 ± 1149.85 | 1966.75 ± 2878.54 | 959.39 ± 742.67 |
| CCL23 (MIPF-1), pg/mL | 205.59 ± 191.76 | 210.22 ± 158.85 | 269.66 ± 195.1 | 267.27 ± 228.33 | 289.70 ± 286.72 |
| CCL24 (Eotaxin-2), pg/mL | 1256.85 ± 952.16 | 884.97 ± 554.68 | 798.94 ± 550.09 | 1348.68 ± 2144.21 | 706.87 ± 823.25 |
| CCL25 (TECK), pg/mL | 1605.47 ± 686.13 | 1769.93 ± 568.76b | 1424.50 ± 699.98 | 1885.03 ± 766.18b | 950.46 ± 625.88b |
| CCL26 (Eotaxin-3), pg/mL | 107.57 ± 35.88a | 120.44 ± 34.02 | 105.16 ± 42.25a | 138.08 ± 51.94a | 79.36 ± 46.38a |
| CCL27 (CTACK), pg/mL | 84.67 ± 44.36b | 68.62 ± 32.69f | 71.31 ± 27.67f | 76.85 ± 36.20g | 36.87 ± 18.29b,d,f,g |
| **Serious cases, n** | | | | | |
| CCL1, pg/mL | — | — | — | — | — |
| CCL2, pg/mL | — | — | — | — | — |
| CCL3, pg/mL | — | — | — | — | — |
| CCL7, pg/mL | — | — | — | — | — |
| CCL8, pg/mL | — | — | — | — | — |
| CCL9, pg/mL | — | — | — | — | — |
| CCL10, pg/mL | — | — | — | — | — |
| **Noninflammatory, mean ± SD** | | | | | |
| CCL1, pg/mL | — | — | — | — | — |
| CCL2 (MCP-1), pg/mL | — | — | — | — | — |
| CCL3 (MIP-1α), pg/mL | — | — | — | — | — |
| CCL7 (MCP-3), pg/mL | — | — | — | — | — |
| CCL8 (MCP-2), pg/mL | — | — | — | — | — |
| CCL9 (MIP-3β), pg/mL | — | — | — | — | — |
| CCL10 (MIP-3α), pg/mL | — | — | — | — | — |
| **Serious cases, n** | | | | | |
| CCL1, pg/mL | — | — | — | — | — |
| CCL2, pg/mL | — | — | — | — | — |
| CCL3, pg/mL | — | — | — | — | — |
| CCL7, pg/mL | — | — | — | — | — |
| CCL8, pg/mL | — | — | — | — | — |
| CCL9, pg/mL | — | — | — | — | — |
| CCL10, pg/mL | — | — | — | — | — |

(continued)
Table 4. (continued)

| Chemokines | EV71+ | CA16+ | EVG+ | EVG− | Control |
|------------|-------|-------|------|------|---------|
| CXCL16, pg/mL | — | 160.02 | — | 664.37 | — |
| CX3CL1, pg/mL | — | 739.88 | — | 2476.29 | — |
| MIF, pg/mL | — | 989.60 | — | 11955.62 | — |

Abbreviation: HFMD, hand, foot, and mouth disease; OV, over the highest level.

*P < .05 of EV71-infected case versus non-EV-infected case.
*P < .05 of EV71-infected case versus placebo.
*P < .05 of CA16-infected case versus non-EV-infected case.
*P < .05 of CA16-infected case versus placebo.
*P < .05 of EV-infected case versus non-EV-infected case.
*P < .05 of EV-infected case versus placebo.
*P < .05 of non-EV-infected case versus placebo.

Figure 1. Neutralizing antibodies against EV71 from the 60 patients with HFMD caused by different pathogens.

and phase III trial of an EV71 inactivated vaccine had demonstrated effective immune protection induced in the individuals infected by EV71 or immunized by the vaccine. Thus, repeat HFMD infection might reflect an infection by the different pathogen or that the abnormal immune response might be related to CA16 or EVG infection.

Taken together, our results suggest the importance of HFMD in determining the exact pathogen when considering the common clinical manifestations induced by the infection of different viruses.

Acknowledgments

Many thanks all the investigators from Guangxi Provincial Center for Disease Control and Prevention, Guilin City Center for Disease Control and Prevention, Yangshuo County Center for Disease Control and Prevention, Lipu County Center for Disease Control and Prevention, Yongfu County Center for Disease Control and Prevention, Lingui County Center for Disease Control and Prevention, Lingchuan County Center for Disease Control and Prevention, Xin’an County Center for Disease Control and Prevention and Quanzhou County Center for Disease Control and Prevention who worked on the trial.

Author Contributions

QL contributed to conception and design, contributed to acquisition, critically revised manuscript, gave final approval, agrees to be accountable for all aspects of work ensuring integrity and accuracy; YZ contributed to conception and design, contributed to analysis and interpretation of data, drafted manuscript, critically revised manuscript, gave final approval and agrees to be accountable for all aspects of work ensuring integrity and accuracy; JW contributed to acquisition and analysis of data, critically revised manuscript, gave final approval, JP contributed to acquisition, critically revised manuscript, gave final approval, JP contributed to acquisition, critically revised manuscript, gave final approval and agrees to be accountable for all aspects of work ensuring integrity and accuracy, LL contributed to acquisition, given final approval and agrees to be accountable for all aspects of work ensuring integrity and accuracy, CY contributed to acquisition, critically revised manuscript and gave final approval; YL, WL, GL, MF, YL, SF, LC, contributed to acquisition and analysis of data and gave final approval.

Authors’ Note

Authors Jingjing Wang and Jing Pu contributed equally to this study.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Basic Research Program (2011CB504903), the National High-Tech R&D Program (2012AA02A404), the Technology Development Research Institutes (2013EG150137), the State Project for Essential Drug Research and Development (2012ZX09101319 and 2014ZX09102042) and Yunnan Province Project (2013FA024, 2014FB191 and 2014HB066).
References

1. Lin TY, Chang LY, Hsia SH, et al. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. *Clin Infect Dis*. 2002;34(suppl 2):S52-S57.

2. Tu PV, Thao NT, Perera D, et al. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. *Emerg Infect Dis*. 2007;13:1733-1741.

3. Wu Y, Yeo A, Phoon MC, et al. The largest outbreak of hand, foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. *Int J Infect Dis*. 2010;14:e1076-e1081.

4. Yang F, Ren L, Xiong Z, et al. Enterovirus 71 outbreak in the People’s Republic of China in 2008. *J Clin Microbiol*. 2009;47:2351-2352.

5. Ministry of Public Health of the People’s Republic of China. The annual national report of infectious diseases at 2008. http://www.nhfpc.gov.cn/mohbgt/s9505/200902/39079.shtml. Published February 2, 2009. Accessed December 25, 2015.

6. Ministry of Public Health of the People’s Republic of China. The annual national report of infectious diseases at 2009. http://www.chinaaecd.cn/n272442/n272530/n272757/35766.html. Published February 24, 2010. Accessed December 25, 2015.

7. Ministry of Public Health of the People’s Republic of China. The annual national report of infectious diseases at 2010. http://www.chinaaecd.cn/n272442/n272530/n272757/41265.html. Published February 14, 2011. Accessed December 25, 2015.

8. Ministry of Public Health of the People’s Republic of China. The annual national report of infectious diseases at 2011. http://www.gov.cn/gzdzt/2012-02/10/content_2063647.htm. Published February 10, 2012. Accessed December 25, 2015.

9. National Health and Family Planning Commission of the People’s Republic of China. The annual national report of infectious diseases at 2012. http://www.nhfpc.gov.cn/wsb/pyqxx/201303/f02d91321f52a66a9df357a53b-d0c0f0.shtml. Published 2013. Accessed December 25, 2015.

10. National Health and Family Planning Commission of the People’s Republic of China. The annual national report of infectious diseases at 2013. http://www.nhfpc.gov.cn/jkj/s3578/201402/26700e8a83c04205913a106545069a11.shtml. Published 2014. Accessed December 25, 2015.

11. National Health and Family Planning Commission of the People’s Republic of China. The annual national report of infectious diseases at 2014. http://news.hexun.com/2015-02-16/173422318.html. Published 2015. Accessed December 25, 2015.

12. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. *Lancet Neurol*. 2010;9:1097-1105.

13. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. *FEMS Microbiol Rev*. 2002;26:91-107.

14. Lum LC, Wong KT, Lam SK, et al. Fatal enterovirus 71 encephalomyelitis. *J Pediatr*. 1998;133:795-798.

15. Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. *N Engl J Med*. 1999;341:929-935.

16. Prager P, Nolan M, Andrews IP, Williams GD. Neurogenic pulmonary edema in enterovirus 71 encephalitis is not uniformly fatal but causes severe morbidity in survivors. *Pediatr Crit Care Med*. 2003;4:377-381.

17. Zimmerman RD. MR imaging findings of enteroviral encephalomyelitis: an outbreak in Taiwan. *AJNR Am J Neuroradiol*. 1999;20:1775-1776.

18. Chang LY, Lin TY, Hsu KH, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. *Lancet*. 1999;354:1682-1686.

19. Kapusinszky B, Szomor KN, Farkas A, Takaes M, Berencsi G. Detection of non-polio enteroviruses in Hungary 2000-2008 and molecular epidemiology of enterovirus 71, coxsackievirus A16, and echovirus 30. *Virus Genes*. 2010;40:163-173.

20. Li L, Ge Y, Yang H, et al. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People’s Republic of China. *J Clin Microbiol*. 2005;43:3835-3839.

21. Wong KT, Munisamy B, Ong KC, et al. The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. *J Neuropathol Exp Neurol*. 2008;67:162-169.

22. Zhang Y, Cui W, Liu L, et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. *Lab Invest*. 2011;91:1337-1350.

23. Gong X, Zhou J, Zhu W, et al. Excessive proinflammatory cytokine and chemokine responses of human monocyte-derived macrophages to enterovirus 71 infection. *BMC Infect Dis*. 2012;12:224.

24. Zeng M, Zheng X, Wei R, et al. The cytokine and chemokine profiles in patients with hand, foot and mouth disease of different severities in Shanghai, China, 2010. *PLoS Negl Trop Dis*. 2013;7:e2599.

25. Zhang Y, Liu H, Wang L, et al. Comparative study of the cytokine/chemokine response in children with differing disease severity in enterovirus 71-induced hand, foot, and mouth disease. *PLoS One*. 2013;8:e67430.

26. Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. *Lancet Infect Dis*. 2014;14:308-318.

27. Glass RI, Breshees J, Jiang B, et al. Gastroenteritis viruses: an overview. *Novartis Found Symp*. 2001;238:5-19.

28. Wang J, Qi S, Zhang X, et al. Coxsackievirus A16 infection does not interfere with the specific immune response induced by an enterovirus 71 inactivated vaccine in rhesus monkeys. *Vaccine*. 2014;32:4436-4442.

29. Zou XN, Zhang XZ, Wang B, Qiu YT. Etiologic and epidemiologic analysis of hand, foot, and mouth disease in Guangzhou city: a review of 4,753 cases. *Braz J Infect Dis*. 2012;16:457-465.
30. Ministry of Public Health of the People’s Republic of China. The Chinese guideline for HFMD diagnosis and treatment. http://www.gdwst.gov.cn/a/zcwj/201004227660.html. Published April 20, 2010. Accessed December 25, 2015.
31. Chen H, Zhang Y, Yang E, et al. The effect of enterovirus 71 immunization on neuropathogenesis and protein expression profiles in the thalamus of infected rhesus neonates. *Virology*. 2012;432:417-426.
32. Gosens R, Rieks D, Meurs H, et al. Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. *Eur Respir J*. 2009;34:1436-1443.
33. Dong C, Liu L, Zhao H, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. *Vaccine*. 2011;29:6269-6275.
34. Zhang Y, Wang L, Liao Y, et al. Similar protective immunity induced by an inactivated enterovirus 71 (EV71) vaccine in neonatal rhesus macaques and children. *Vaccine*. 2015;33:6290-6297.
35. Zhang J, Sun J, Chang Z, Zhang W, Wang Z, Feng Z. Characterization of hand, foot, and mouth disease in China between 2008 and 2009. *Biomed Environ Sci*. 2011;24:214-221.
36. Lin TY, Chang LY, Huang YC, Hsu KH, Chiu CH, Yang KD. Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. *Acta Paediatr*. 2002;91:632-635.
37. Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. *Clin Infect Dis*. 2003;36:269-274.
38. Oberste MS, Maher K, Kilpatrick DR, Pallansch MA. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. *J Virol*. 1999;73:1941-1948.
39. Lin Y, Wen K, Pan Y, Wang Y, Che X, Wang B. Cross-reactivity of anti-EV71 IgM and neutralizing antibody in series sera of patients infected with enterovirus 71 and coxsackievirus A16. *J Immunassay Immunochem*. 2011;32:233-243.
40. Shih SR, Ho MS, Lin KH, et al. Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998. *Virus Res*. 2000;68:127-136.
41. Singh S, Poh CL, Chow VT. Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore (2000). *Microbiol Immunol*. 2002;46:801-808.
42. Mei J, Liu Y, Dai N, et al. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. *Immuity*. 2010;33:106-117.
43. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. *Brain*. 2006;129:200-211.
44. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. *Nat Rev Immunol*. 2003;3:569-581.
45. Ansel KM, Harris RB, Cyster JG. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. *Immunity*. 2002;16:67-76.
46. Yang J, Yang C, Guo N, et al. Type I interferons triggered through the toll-like receptor 3-TRIF pathway control coxsackievirus A16 infection in young mice. *J Virol*. 2015;89:10860-10867.